drugset / Trial / NCT02132234
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Phase 4
Unknown
100 enrolled
Jagiellonian University
Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The aim of this study is to evaluate the influence of anti tumor necrosis factor-alpha (TNF-α) treatment on blood pressure, endothelial function and immune cell phenotype in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Certolizumab | Protein / enzyme biologic | 200 mg | Subcutaneous |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Subject | Infliximab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |